↓ Skip to main content

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors

Overview of attention for article published in Investigational New Drugs, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs
1 blog
twitter
1 X user

Citations

dimensions_citation
108 Dimensions

Readers on

mendeley
77 Mendeley
Title
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Published in
Investigational New Drugs, March 2015
DOI 10.1007/s10637-015-0221-y
Pubmed ID
Authors

Quincy Siu-Chung Chu, Randeep Sangha, Jennifer Spratlin, Larissa J. Vos, John R. Mackey, Alexander J. B. McEwan, Peter Venner, Evangelos D. Michelakis

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
United States 1 1%
Unknown 75 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 18%
Researcher 10 13%
Student > Master 7 9%
Student > Doctoral Student 6 8%
Student > Bachelor 6 8%
Other 18 23%
Unknown 16 21%
Readers by discipline Count As %
Medicine and Dentistry 19 25%
Biochemistry, Genetics and Molecular Biology 13 17%
Agricultural and Biological Sciences 6 8%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Other 15 19%
Unknown 17 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#4,117,309
of 24,503,376 outputs
Outputs from Investigational New Drugs
#138
of 1,238 outputs
Outputs of similar age
#49,221
of 265,487 outputs
Outputs of similar age from Investigational New Drugs
#4
of 12 outputs
Altmetric has tracked 24,503,376 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,238 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.